Natalia V. Buchinskaya

Dr. Natalia V. Buchinskaya

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
Mikhail KostikMikhail Kostik
Mikhail Kostik
MDMargarita F. Dubko
Margarita F. Dubko
VMVera V. Masalova
Vera V. Masalova
LSLudmila S. Snegireva
Ludmila S. Snegireva
TKTatyana L. Kornishina
Tatyana L. Kornishina
VCVyacheslav Chasnyk
Vyacheslav Chasnyk
The purpose of our study was to detect early clinical and laboratory signs that help to discriminate macrophage activation syndrome (MAS) from active systemic juvenile idiopathic arthritis (SJIA) without MAS.Our retrospective study was based on reviewing the medical charts of the children admitted to the rheumatology department with active SJIA and definite MAS (n = 18) and without MAS (n = 40). We evaluated the data related to SJIA and MAS at the moment of the patient׳s admission. If the patient had signs of MAS since admission or developed definite MAS later during this flare, he was referred to the main group. The children who did not have MAS during the flare episode and did not have MAS in the past medical history were in the control group. We calculated the cutoff points for MAS parameters, performed the analysis of sensitivity and specificity, identified the predictors, and provided the preliminary diagnostic rule through "the-number-of-criteria-present" approach.The clinical signs were relevant to MAS in SJIA: oligoarticular disease course (OR = 5.6), splenomegaly (OR = 67.6), hemorrhages (OR = 33.0), and respiratory failure (OR = 11.3). The involvement of wrist (OR = 0.2), MCP (OR = 0.1), and PIP joints (OR = 0.1) was protective against MAS development. The best cutoffs for laboratory parameters were PLT ≤ 211 × 10(9)/l, WBC ≤ 9.9 × 10(9)/l, AST > 59.7U/l, LDH > 882U/l, albumin ≤ 2.9g/dl, ferritin > 400μg/l, fibrinogen ≤ 1.8g/l, and proteinuria. The laboratory variables were more precise in the discrimination of early MAS than clinical: any 3 or more laboratory criteria provided the highest specificity (1.0) and sensitivity (1.0) and OR = 2997.We detected clinical and laboratory markers and created preliminary diagnostic (laboratory) guidelines for early discrimination of MAS in active SJIA.

23 January 2015 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
Mikhail KostikMikhail Kostik
Mikhail Kostik
MDMargarita F Dubko
Margarita F Dubko
VMVera V Masalova
Vera V Masalova
LSLudmila S Snegireva
Ludmila S Snegireva
TKTatyana L Kornishina
Tatyana L Kornishina
VCVyacheslav Chasnyk
Vyacheslav Chasnyk
Systemic juvenile idiopathic arthritis (SoJIA) is the most striking form of juvenile idiopathic arthritis. The aim of our study was to evaluate the clinical responses and outcomes of children with SoJIA to IL-6 blockade using two different tocilizumab (TCZ) treatment protocols designed for milder and more severe SoJIA patient groups, and evaluate the possibility of achieving biologic-free remission.

13 October 2021 in Pediatrician (St. Petersburg)
Verified
Journal Article
Open access
PDF file
VGVictoria N. Gorbunova
Victoria N. Gorbunova
NBNatalia V. Buchinskaya
Natalia V. Buchinskaya
БВБучинская Наталья Валерьевна
Бучинская Наталья Валерьевна
Mucopolysaccharidosis (MPS) are a genetically heterogeneous group of rare monogenic metabolic diseases associated with hereditary insufficiency of lysosomal enzymes involved in the catabolism of glycosaminoglycans, or mucopolysaccharides. The pathogenesis of MPS is due to the accumulation of non-cleaved glycosaminoglycans in lysosomes, which can destroy cells. All MPS are characterized by a polysystemic manifestation, the simultaneous involvement of many organs and tissues in the pathological process, first of all, connective tissues, bones and cartilaginous. This review presents the epidemiology, clinical, biochemical, and molecular genetic characteristics of MPS types I and II, caused by the recessive mutations in the alpha-L-iduronidase and iduronate-2-sulfatase genes, respectively, and by the accumulation of dermatan and heparan sulfate. Each of these diseases is characterized by clinical polymorphism, especially observed in MPS I, which often manifests in a severe form of Hurler syndrome, but can also occur in a milder form of Scheie syndrome. Currently, there is an increased interest in MPS in the world due to the identification of the spectrum and frequencies of mutations in theIDUAandIDSgenes in various populations, including in Russia, and the practical availability of methods for individual molecular diagnostics. The description of the existing experimental models, their role in the study of the biochemical basis of the pathogenesis of these severe hereditary diseases and the development of various therapeutic approaches are given. Discusses the possibility of early diagnosis of MPS I and II types based on neonatal screening in order to increase the effectiveness of their prevention and treatment, as well as the advantages and disadvantages of the main approaches to the treatment of these serious diseases, such as hematopoietic stem cell transplantation, enzyme replacement and substrate-reducing therapy. A clinical example of a combination therapy for a severe form of mucopolysaccharidosis type I Hurler syndrome is presented

13 December 2021 in Pediatrician (St. Petersburg)
Verified
Journal Article
Open access
PDF file
VGV. N. Gorbunova
V. N. Gorbunova
NBNatalia V. Buchinskaya
Natalia V. Buchinskaya
The review describes the clinical, biochemical and molecular genetic characteristics of autosomal recessive mucopolysaccharidosis type III, or Sanfilippo syndrome. This is a genetically heterogeneous group of rare, but similar in nature, diseases caused by a deficiency of one of the four lysosomal enzymes involved in the degradation of heparan sulfate. All types of mucopolysaccharidosis III are characterized by severe degeneration of the central nervous system in combination with mild somatic manifestations, which is explained by the accumulation of high concentrations of heparan sulfate in the lysosomes of various cells, including the central nervous system. The primary biochemical defect in the most common type of mucopolysaccharidosis IIIA, occurring with a frequency of 1 : 105 and presented in 60% of all cases of the disease, is heparan-N-sulfatase, or sulfamidase deficiency. Mucopolysaccharidosis IIIB type occurs twice less often and accounts for about 30% of all cases of Sanfilippo syndrome. It is caused by the presence of inactivating mutations in the lysosomal -N-acetylglucosaminidase gene. Mucopolysaccharidosis IIIC and IIID are 4% and 6%, and occur at frequencies of 0.7 and 1.0 : 106. Mucopolysaccharidosis IIIC is caused by inactivating mutations in the gene of membrane-bound lysosomal acetyl-CoA:-glucosaminid-N-acetyltransferase, or N-acetyltransferase. Mucopolysaccharidosis IIID is based on the deficiency of lysosomal N-acetylglucosamine-6-sulfatase. The role of experimental models in the study of the biochemical basis of the pathogenesis of Sanfilippo syndrome and the development of various therapeutic approaches are discussed. The possibility of neonatal screening, early diagnosis, prevention and pathogenetic therapy of these severe lysosomal diseases are considered. As an example, a clinical case of diagnosis and treatment of a child with type IIIB mucopolysaccharidosis is presented.

11 May 2014 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
NBNatalia V. Buchinskaya
Natalia V. Buchinskaya
ICI. А. Chikova
I. А. Chikova
EIE. А. Isupova
E. А. Isupova
ОKО. V. Kalashnikova
О. V. Kalashnikova
МKМ. М. Kostik
М. М. Kostik
VCV. G. Chasnyk
V. G. Chasnyk
Мукополисахаридозы — группа наследственных нарушений обмена веществ, характеризующаяся накоплением гликозаминогликанов вследствие дефицита специфических лизосомных ферментов. Цель исследования: изучить влияние ферментзаместительной терапии на соматическое состояние и психомоторное развитие детей с мукополисахаридозом I и II типа различной степени тяжести в динамике и оценить ее эффективность. Пациенты и методы: в исследовании использованы данные пятилетнего наблюдения за 13 пациентами с мукополисахаридозом I и II типа. В ходе работы выполнен анализ эффективности терапии по следующим критериям: данные объективных осмотров, ультразвуковое исследование печени, селезенки и сердца, количественное определение экскреции гликозаминогликанов мочи, оценка суставного и внесуставного поражения по шкале JADI, оценка социального возраста и социального коэффициента о шкале Долла. Результаты: получены достоверные различия в содержании гликозаминогликанов мочи, а также по результатам объективной оценки размеров печени и селезенки и ультразвукового исследования площади селезенки через 6 и 12 мес лечения по сравнению с исходными данными. Зарегистрировано достоверное снижение показателя социального коэффициента на первом этапе терапии, далее различия носят незначительный характер. Существенной динамики суставного статуса на фоне терапии обнаружено не было, что связано со стабилизацией процесса. Не получено достоверных доказательств как положительной, так и отрицательной динамики по поражению миокарда, ультразвуковым характеристикам размеров долей печени. Выводы: ферментзаместительная терапия является эффективным методом лечения соматических проявлений различных типов мукополисахаридозов.

18 April 2022 in Pediatrician (St. Petersburg)
Verified
Journal Article
Open access
PDF file
VGVictoria N. Gorbunova
Victoria N. Gorbunova
NBNatalia V. Buchinskaya
Natalia V. Buchinskaya
БВБучинская Наталья Валерьевна
Бучинская Наталья Валерьевна
The review is devoted to the clinical, biochemical, and molecular genetic characteristics of autosomal recessive mucopolysaccharidoses (MPS) types IV, VI, and VII. MPS IV type, or Morquios syndrome, is represented by 2 types A and B. The cause of the most frequent MPS IVA is hereditary deficiency of galactose-6-sulfatase, due to the presence of inactivating mutations in the GALNS gene. The pathogenetic basis of the disease is associated with excessive accumulation in lysosomes, mainly of cartilage tissue of keratan sulfate and chondroitin-6-sulfate. Main clinical manifestations of MPS IVA are dwarfism and progressive deformity of the spine, sternum, and knees. The milder MPS IVB is due to hereditary -galactosidase deficiency and is an allelic variant of GM1 gangliosidosis. The cause of MPS VI, or MarotoLamy syndrome, and MPS VII, or Sly syndrome, is hereditary deficiency of arylsulfatase B and -glucuronidase, respectively. The pathogenesis of these diseases is due to the excessive accumulation of dermatan sulfate and, in the second case, additionally, heparan sulfate. Patients with type VI and VII MPS have a Hurler-like phenotype, but in the first case, intellectual deficiency are usually absent, while in Sly syndrome, moderate mental retardation is observed. The possibility of neonatal screening and early diagnosis of these MPS in order to increase the effectiveness of their prevention and treatment is discussed. The importance of experimental models for studying the molecular basis of the pathogenesis of these severe hereditary diseases and the development of various therapeutic approaches, such as bone marrow transplantation, enzyme replacement therapy and substrate-reducing therapy, is emphasized. Descriptions of clinical cases of MPS IVA and VI types are presented.